NCT06473103 Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
| NCT ID | NCT06473103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Basal Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2024-10-29 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2024-10-29 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the use of two photon fluorescence microscopy for detecting residual basal cell carcinoma during standard local excision.
Eligibility Criteria
Inclusion Criteria: * Undergoing treatment for basal cell carcinoma without Mohs surgery at the performance site * Able to read and understand consent form Exclusion Criteria: * None
Contact & Investigator
Michael Giacomelli
PRINCIPAL INVESTIGATOR
University of Rochester
Frequently Asked Questions
Who can join the NCT06473103 clinical trial?
This trial is open to participants of all sexes, studying Basal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06473103 currently recruiting?
Yes, NCT06473103 is actively recruiting participants. Contact the research team at mgiacome@ur.rochester.edu for enrollment information.
Where is the NCT06473103 trial being conducted?
This trial is being conducted at Victor, United States.
Who is sponsoring the NCT06473103 clinical trial?
NCT06473103 is sponsored by University of Rochester. The principal investigator is Michael Giacomelli at University of Rochester. The trial plans to enroll 52 participants.